Towards precision medicine for triple negative breast cancer
The Glucose transporter 1 (GLUT1) chemical probe story is an excellent example on how probes can be applied to identify patient populations and how these react to inhibition.
Triple Negative Breast Cancer (TNBC) is a highly aggressive form of breast cancer representing 15–20% of breast cancer cases but accounts for 25% of deaths. A recent study showed that retinoblastoma tumor suppressor (RB1)-positive TNBC patient samples are sensitive to GLUT1 inhibition by the chemical probe BAY-876. The levels of RB1 dictate BAY-876 sensitivity in patient samples.
These results suggest that clinical evaluation of GLUT1 inhibition in stratified TNBC patients may affect treatment outcome.
Figure. GLUT1 inhibition by BAY-876 blocks growth of RB1 positive triple negative breast cancer.
For more information about the BAY-876 chemical probe visit the Chemical Probes Portal:
Chemical probe BAY-876 Negative control of BAY-876: BAY-588